Aptose Biosciences Inc
LTI0
Company Profile
Business description
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.
Contact
66 Wellington Street West
Suite 5300, TD Bank Tower Box 48
TorontoONM5K 1E6
CANT: +1 647 479-9828
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
13
Stocks News & Analysis
stocks
Will undervalued ASX share show progress in results?
Investors will get to see if the new strategy and capital management framework are working.
stocks
10 best US dividend aristocrats to buy now for 2026
These undervalued stocks with economic moats have increased their dividends for 25 consecutive years or more.
stocks
What to expect from the January Fed meeting
Central bankers are likely to hold interest rates steady, but Wall Street is focused on life after Powell.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,250.60 | 50.70 | -0.55% |
| CAC 40 | 8,059.17 | 93.65 | -1.15% |
| DAX 40 | 24,773.29 | 121.15 | -0.49% |
| Dow JONES (US) | 49,003.41 | 408.99 | -0.83% |
| FTSE 100 | 10,164.86 | 42.94 | -0.42% |
| HKSE | 27,826.91 | 699.96 | 2.58% |
| NASDAQ | 23,817.10 | 215.74 | 0.91% |
| Nikkei 225 | 53,358.71 | 25.17 | 0.05% |
| NZX 50 Index | 13,412.87 | 98.01 | -0.73% |
| S&P 500 | 6,978.60 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,933.90 | 40.40 | -0.45% |
| SSE Composite Index | 4,151.24 | 11.33 | 0.27% |